The Management Board of the Croatian Health Insurance Fund (HZZO) has included the drug Spinraza (nusinersen) in the basic list of medicines for the treatment of spinal muscular atrophy types 1, 2, and 3 for children up to 18 years old who are not on mechanical ventilation (respirator), it was announced on Tuesday after the meeting.
The basic list of medicines has been expanded to include the drug folitropin delta for the treatment of infertility, reserve antibiotics ceftazidim+avibaktam and ceftaroline fosamil, tenofovir alafenamide for the treatment of chronic hepatitis B, the drugs okrelizumab and cladribine for the treatment of multiple sclerosis, the drug idebenone for the treatment of Leber’s hereditary optic neuropathy, and the combination of beclometasone+formoterol+glycopyrronium for the treatment of chronic obstructive pulmonary disease, while two new indications have been approved for the drug regorafenib – for the treatment of gastrointestinal stromal tumors and hepatocellular carcinoma.
>>>Kujundžić: HZZO achieved a profit of 241 million kuna
Supplementary list of medicines
Two new drugs have been included in the supplementary list of medicines – eletriptan for the treatment of migraine headaches and tafluprost+timolol for glaucoma.
An additional 98 new packages have been included on both lists – generic and clinical parallels as well as new forms of already existing drugs on the list.
By adding new drugs to the list, the range of medicines that insured persons can obtain for their treatment at the expense of mandatory health insurance is expanded.
Additional 5000 MRI procedures
HZZO will, it was announced, contract an additional 5000 magnetic resonance imaging (MRI) procedures from May 1 to December 31 of this year, in order to reduce the National Waiting List, according to the directive of the Ministry of Health.
After the conducted tender, the most favorable bidders have been selected with whom the implementation and payment of the MRI procedure will be contracted in all regions, proportionate to the number of available additional procedures and the expressed interest of the bidders.
